Results

Total Results: 10 records

Showing results for "vte".

1. Archived: Evidence Summary: Breast and Ovarian Cancer: BRCA Genetic Testing, September 2005 | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-cancer--brca-testing-ovarian-cancer-screeni
   September 15, 2005 - using estrogen Tamoxifen, 3573; placebo, 3566 50 Total 69 101 0.68 (0.50-0.92) VTE … using estrogen Tamoxifen, 6576; placebo, 6599 55 Total 124 244 0.51 (0.41-0.63) ** VTE … using estrogen Tamoxifen, 1238; placebo, 1233 70 Total 34 36 0.94 (0.59-1.49) ** VTE … using estrogen Tamoxifen, 2700; placebo, 2708 46 Total 19 22 0.87 (0.47-1.60) ** VTE … estrogen receptor; NA = not available; NS = not statistically significant; PE = pulmonary embolism; VTE

2. Archived: Evidence Summary: Breast and Ovarian Cancer: BRCA Genetic Testing, September 2005 | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-and-ovarian-cancer-brca-testing-screening-2005
   September 15, 2005 - using estrogen Tamoxifen, 3573; placebo, 3566 50 Total 69 101 0.68 (0.50-0.92) VTE … using estrogen Tamoxifen, 6576; placebo, 6599 55 Total 124 244 0.51 (0.41-0.63) ** VTE … using estrogen Tamoxifen, 1238; placebo, 1233 70 Total 34 36 0.94 (0.59-1.49) ** VTE … using estrogen Tamoxifen, 2700; placebo, 2708 46 Total 19 22 0.87 (0.47-1.60) ** VTE … estrogen receptor; NA = not available; NS = not statistically significant; PE = pulmonary embolism; VTE

3. Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/3HxQuXnyqHpUKNqjB7hWBw
   September 01, 2005 - estrogen receptor; NA � not available; NS � not statistically significant; PE � pulmonary embolism; VTE … Table 5—Continued Adverse Effects Type Treatment Group, n Placebo Group, n Relative Risk (95% CI) VTE … 11 1.18 (0.53–2.63)† Endometrial cancer 11 5 2.2 (0.86–6.06) All-cause death 25 11 2.27 (1.12–4.60)† VTE … 1.59 (0.93–2.77)† Endometrial cancer 36 15 2.53 (1.35–4.97) All-cause death 57 71 0.81 (0.56–1.16)† VTE … 0.50–8.01)† Stroke 9 5 1.81 (0.61–5.38)† Endometrial cancer NA All-cause death 6 9 0.67 (0.24–1.88)† VTE

4. Final Recommendation Statement: Breast Cancer: Medication Use to Reduce Risk | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/breast-cancer-medications-for-risk-reduction
   September 03, 2019 - ) events, or stroke. 3 When compared with placebo, raloxifene was associated with 7 more cases of VTE … on the STAR trial, more harms were reported with tamoxifen compared with raloxifene: 4 more cases of VTE

5. Recommendation: Breast Cancer: Medication Use to Reduce Risk | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction
   September 03, 2019 - ) events, or stroke. 3 When compared with placebo, raloxifene was associated with 7 more cases of VTE … on the STAR trial, more harms were reported with tamoxifen compared with raloxifene: 4 more cases of VTE

6. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/3Kwu7j_WfCFQSnSzqrDWwt
   June 20, 2019 - CHD) events, or stroke.3 When compared with placebo, raloxifene was associated with 7 more cases of VTE … on the STAR trial, more harms were reported with tamoxifen compared with raloxifene: 4 more cases of VTE

7. Archived: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction-2013
   September 15, 2013 - general, women taking medications for breast cancer risk reduction are less likely to experience a VTE … Women with a personal or family history of venous thromboembolism are at higher risk for these adverse

8. Zvvry6Wa4Sgj-Ejb3Brcvy (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/zVVRY6wa4Sgj-EJb3BRcVy
   November 01, 2013 - Effects In general, women receiving medications for breast cancer risk reduction are less likely to have VTE … Women with a personal or family history of venous thromboembolism are at higher risk for these ad- verse

9. Evidence Summary: Breast Cancer: Medication Use to Reduce Risk | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-cancer-medications-for-risk-reduction
   September 03, 2019 - with tamoxifen 0.97 (0.86-1.12) 2 NA NA 1.05 (0.87-1.28) 2 NA NA Harms Venous … thromboembolism j 0.75 (0.60-0.93) d 4 (1-7) more with tamoxifen 1.93 (1.33-2.68) 4 0.91 ( … Project; PE, pulmonary embolism; RR, risk ratio; RUTH, Raloxifene Use for the Heart; SE, standard error; VTE … , venous thromboembolism.

10. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/-TsBkyewVoFpC7htRmzWJa
    September 03, 2019 - Project; PE, pulmonary embolism; RR, risk ratio; RUTH, Raloxifene Use for the Heart; SE, standard error; VTE … , venous thromboembolism. a Numbers of events reduced for benefits or increased for harms vs comparator